代谢综合征和前列腺疾病

樊 国瑞, 关 晓海
华北理工大学附属医院 泌尿外科 河北唐山 063000

摘要

摘要：最近许多研究广泛阐明了代谢综合征与前列腺疾病之间的关系，但其潜在机制尚不清楚。我们总结了目前已发表的有关代谢综合征与前列腺疾病相关机制的研究，以帮助更好地理解代谢综合征与前列腺炎、前列腺增生和前列腺癌等前列腺疾病之间的关系。代谢综合征会导致内分泌状态改变、交感神经活动增加以及炎症反应，从而加剧前列腺增生的发展。在前列腺癌中，代谢综合征会导致激素水平改变、胰岛素抵抗和脂肪因子分泌改变。这些机制可能会促进前列腺癌的发展，甚至导致高级别前列腺癌。代谢综合征在前列腺炎中的作用尚不清楚。更好地了解前列腺疾病和代谢综合征的内在机制有助于开发新的疗法、预后指标和药物靶点。

关键词

关键词：代谢综合征；胰岛素抵抗；前列腺炎；良性前列腺增生；前列腺癌

参考

[1]Saklayen M G. The Global Epidemic of the Metabolic Syndrome[J]. Curr Hypertens Rep, 2018, 20 (2)：12.[2]Lin L, Tan W, Pan X, et al. Metabolic Syndrome-Related Kidney Injury： A Review and Update[J]. Front Endocrinol (Lausanne), 2022, 13：904001.[3]Grandl G. Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome[J]. Semin Immunopathol, 2018, 40 (2)：215-224.[4]Lv K, Wu Y, Huang S, et al. Age and metabolic syndrome are associated with unsatisfactory improvement in nocturia after holmium laser enucleation of the prostate[J]. Front Surg, 2022, 9：1063649.[5]Calhoun E A, McNaughton Collins M, Pontari M A, et al. The economic impact of chronic prostatitis[J]. Arch Intern Med, 2004, 164 (11)：1231-1236.[6]Lumeng C N. Innate immune activation in obesity[J]. Mol Aspects Med, 2013, 34 (1)：12-29.[7]Tilg H. Kaser A. Gut microbiome, obesity, and metabolic dysfunction[J]. J Clin Invest, 2011, 121 (6)：2126-2132.[8]Berry S J, Coffey D S, Walsh P C, et al. The development of human benign prostatic hyperplasia with age[J]. J Urol, 1984, 132 (3)：474-479.[9]Chughtai B, Forde J C, Thomas D D, et al. Benign prostatic hyperplasia[J]. Nat Rev Dis Primers, 2016, 2：16031.[10]Egan K B. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms： Prevalence and Incident Rates[J]. Urol Clin North Am, 2016, 43 (3)：289-297.[11]Yim S J, Cho Y S. Joo K J. Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age[J]. Korean J Urol, 2011, 52 (6)：390-395.[12]Ohgaki K, Hikima N, Horiuchi K, et al. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score[J]. Urology, 2011, 77 (6)：1432-1438.[13]Wang S, Mao Q, Lin Y, et al. Body mass index and risk of BPH： a meta-analysis[J]. Prostate Cancer Prostatic Dis, 2012, 15 (3)：265-272.[14]Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome[J]. J Clin Invest, 2004, 114 (12)：1752-1761.[15]Sandhu J S. Prostate cancer and chronic prostatitis[J]. Curr Urol Rep, 2008, 9 (4)：328-332.[16]Rohrmann S, Nelson W G, Rifai N, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III)[J]. Urology, 2007, 69 (4)：708-713.[17]Haider A, Gooren L J, Padungtod P, et al. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men[J]. Andrologia, 2009, 41 (1)：7-13.[18]Ansari M A, Begum D. Islam F. Serum sex steroids,gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia[J]. Ann Saudi Med, 2008, 28 (3)：174-178.[19]Verma S, Wang C H, Li S H, et al. A self-fulfilling prophecy： C-reactive protein attenuates nitric oxide production and inhibits angiogenesis[J]. Circulation, 2002, 106 (8)：913-919.[20]Takeda M, Tang R, Shapiro E, et al. Effects of nitric oxide on human and canine prostates[J]. Urology, 1995, 45 (3)：440-446.[21]Sauzeau V, Le Jeune H, Cario-Toumaniantz C, et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle[J]. J Biol Chem, 2000, 275 (28)：21722-21729.[22]Khan Z A. Chakrabarti S. Endothelins in chronic diabetic complications[J]. Can J Physiol Pharmacol, 2003, 81 (6)：622-634.[23]Vietri M T, D'Elia G, Caliendo G, et al. Hereditary Prostate Cancer： Genes Related, Target Therapy and Prevention[J]. Int J Mol Sci, 2021, 22 (7).[24]Prabhat P, Tewari R, Natu S M, et al. Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study[J]. Indian J Urol, 2010, 26 (4)：502-506.[25]Gillies R J, Pilot C, Marunaka Y, et al. Targeting acidity in cancer and diabetes[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871 (2)：273-280.[26]Trayhurn P. Adipokines： inflammation and the pleiotropic role of white adipose tissue[J]. Br J Nutr, 2022, 127 (2)：161-164.[27]Braun S, Bitton-Worms K. LeRoith D. The link between the metabolic syndrome and cancer[J]. Int J Biol Sci, 2011, 7 (7)：1003-1015.[28]Li H, Stampfer M J, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival[J]. Clin Chem, 2010, 56 (1)：34-43.[29]Yu H. Rohan T. Role of the insulin-like growth factor family in cancer development and progression[J]. J Natl Cancer Inst, 2000, 92 (18)：1472-1489.[30]Chan J M, Stampfer M J, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk： a prospective study[J]. Science, 1998, 279 (5350)：563-566.[31]Gunter J H, Lubik A A, McKenzie I, et al. The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer[J]. Adv Urol, 2012, 2012：248607.[32]Giovannucci E, Rimm E B, Colditz G A, et al. A prospective study of dietary fat and risk of prostate cancer[J]. J Natl Cancer Inst, 1993, 85 (19)：1571-1579.[33]Sekine Y, Osei-Hwedieh D, Matsuda K, et al. High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate[J]. Prostate, 2011, 71(14)：1499-1509.[34]Kulkarni P. Getzenberg R H. High-fat diet, obesity and prostate disease： the ATX-LPA axis?[J]. Nat Clin Pract Urol, 2009, 6 (3)：128-131.[35]Huang M, Narita S, Numakura K, et al. A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling[J]. Prostate,2012, 72 (16)：1779-1788.